Former FDA Commissioner Frank Young Passes Away At 88
From the approval of AZT to the generic drug scandal, Frank Young oversaw many seminal events at US FDA while commissioner from 1984 to 1989. After leaving the agency, he managed the approval of the NDA for Braeburn's opioid dependence drug Probuphine. Young passed away following a short bout with cancer.
You may also be interested in...
The latest drug development news and highlights from our FDA Performance Tracker.
In interviews with “The Pink Sheet,” the last half-dozen FDA commissioners discuss crafting policy on Capitol Hill, building start-up biotechs, consulting and serving on industry boards.
FDA’s “complete response” letter for abuse-resistant buprenorphine for opioid dependence follows an advisory committee that aired concerns about efficacy and adequate dosing, as well as questioning the proposed Risk Evaluation and Mitigation Strategy.